Showing results (211-220 of 242) with videos related to
Sort By:
Pageof 25
Science Translational Medicine|February 8, 2023
Immunotoxin-αCD40 therapy activates innate and adaptive immunity and generates a durable antitumor response in glioblastoma modelsScott Parker, Charlotte McDowall, Luis Sanchez-Perez, et al.Oncotarget|April 12, 2014
Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomasPatrick J Killela, Christopher J Pirozzi, Patrick Healy, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2002
Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomasDavid A Reardon, Gamal Akabani, R Edward Coleman, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 29, 2018
A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant GliomaPatrick C Gedeon, Teilo H Schaller, Satish K Chitneni, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2002
Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant gliomaJennifer A Quinn, James Pluda, M Eileen Dolan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2005
Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study resultsDavid A Reardon, Gamal Akabani, R Edward Coleman, et al.Neuro-Oncology|February 22, 2008
A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boostDavid A Reardon, Michael R Zalutsky, Gamal Akabani, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2006
Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant gliomaDavid A Reardon, Jennifer A Quinn, James J Vredenburgh, et al.Nature Genetics|June 2, 2014
Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomasLiwei Zhang, Lee H Chen, Hong Wan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 26, 2003
Phase II trial of gefitinib in recurrent glioblastomaJeremy N Rich, David A Reardon, Terry Peery, et al.Pageof 25